The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy

Neurology

Volumn 80, Issue 16, 2013, Pages 1465-1471

  Martinez, Ashley ^a   Finegersh, Andrey ^a   Cannon, Dara M ^d   Dustin, Irene ^a   Nugent, Alison ^c   Herscovitch, Peter ^b   Theodore, William H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; FLUORINE 18; FLUOXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; ANTICONVULSIVE AGENT; BENZYLAMINE DERIVATIVE; CYCLOHEXANE DERIVATIVE; DIAGNOSTIC AGENT; N (2 (4 (2 METHOXYPHENYL)PIPERAZINO)) N (2 PYRIDINYL) TRANS 4 FLUOROCYCLOHEXANECARBOXAMIDE; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE; N,N-DIMETHYL-2-(2-AMINO-4-CYANOPHENYLTHIO)BENZYLAMINE; N-(2-(4-(2-METHOXYPHENYL)PIPERAZINO))-N-(2-PYRIDINYL) TRANS-4-FLUOROCYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; EPILEPTIC FOCUS; FEMALE; FUSIFORM GYRUS; HIPPOCAMPUS; HUMAN; INSULA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE EPILEPSY; ANALYSIS OF VARIANCE; BRAIN CORTEX; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETICS; HEMISPHERIC DOMINANCE; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; ONSET AGE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; SEXUAL DEVELOPMENT; STATISTICAL ANALYSIS;

ADULT; AGE OF ONSET; ANALYSIS OF VARIANCE; ANTICONVULSANTS; BENZYLAMINES; CEREBRAL CORTEX; CYCLOHEXANES; DATA INTERPRETATION, STATISTICAL; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPILEPSY, TEMPORAL LOBE; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX CHARACTERISTICS;

MLCS; MLOWN;

EID: 84878755905     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828cf809     Document Type: Article

References (40)

1. Clinckers R, Smolders I, Meurs A, et al. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem 2004;89:834-843.
2. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem 2007;100:857-873.
3. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003;60:749-756.
4. Merlet I, Ostrowsky K, Costes N, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an F-18 MPPF-PET study. Brain 2004:127;900-913.
5. Savic I, Lindstrom P, Gulyas B, Halldin C, Andree B, Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004;62:1343-1351.
6. Giovacchini G, Toczek MT, Bonwetsch R, et al. 5-HT1A receptors are reduced in temporal lobe epilepsy after partialvolume correction. J Nucl Med 2005;46:1128-1135.
7. Hasler G, Bonwetsch R, Giovacchini G, et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007;62:1258-1264.
8. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47:246-249.
9. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin (1A) receptor binding measured by positron emission tomography with C-11 WAY-100635-Effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-180.
10. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a carbonyl-C-11 WAY100635 positron emission tomography study. Biol Psychiatry 2006;59:106-113.
11. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007;34:865-877.
12. Theodore WH, Hasler G, Giovacchini G, et al. Reduced hippocampal 5-HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007;48:1526-1530.
13. Lothe A, Didelot A, Hammers A, et al. Comorbidity between temporal lobe epilepsy and depression: a F-18 MPPF PET study. Brain 2008;131:2765-2782.
14. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004;61:1271-1279.
15. Cannon DM, Ichise M, Fromm SJ, et al. Serotonin transporter binding in bipolar disorder assessed using C-11 DASB and positron emission tomography. Biol Psychiatr 2006;60:207-217.
16. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and C-11 DASB: comparison with bipolar disorder. Biol Psychiatry 2007;62:870-877.
17. Parsey RV, Hastings RS, Oquendo MA, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006;163:52-58.
18. Oquendo MA, Hastings RS, Huang YY, et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry 2007;64:201-208.
19. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389.
20. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of C-11-labeled 2-(phenylthio) araalkylamines. JMed Chem 2000;43:3103-3110.
21. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16:620-633.
22. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143-156.
23. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric Imaging methods: application to C-11 DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003;23:1096-1112.
24. Kim JS, Ichise M, Sangare J, Innis RB. PET imaging of serotonin transporters with C-11 DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med 2006;47:208-214.
25. Theodore WH, Giovacchini G, Bonwetsch R, et al. The effect of antiepileptic drugs on 5-HT1A receptor binding measured by positron emission tomography. Epilepsia 2006;47:499-503.
26. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc 1961;56:52-64.
27. Manna I, Labate A, Gambardella A, et al. Serotonin transporter gene (5-HTT): association analysis with temporal lobe epilepsy. Neurosci Lett 2007;421:52-56.
28. Schenkel LC, Bragatti JA, Torres CM, et al. Serotonin transporter gene (5-HTT) polymorphisms and temporal lobe epilepsy. Epilepsy Res 2011;95:152-157.
29. Kauffman MA, Consalvo D, Gonzalez-Morón D, Aguirre F, D'Alessio L, Kochen S. Serotonin transporter gene variation and refractory mesial temporal epilepsy with hippocampal sclerosis, Epilepsy Res 2009;85:231-234.
30. Hrvoje H, Jasminka S, Lipa C-S, Vida D, Branimir J. Association of serotonin transporter promoter (5-HTTLPR) and intron 2 (VNTR-2) polymorphisms with treatment response in temporal lobe epilepsy. Epilepsy Res 2010;91:35-38.
31. Stefulj J, Bordukalo-Niksic T, Hecimovic H, Demarin V, Jernej B. Epilepsy and serotonin (5-HT): variation of 5-HTrelated genes in temporal lobe epilepsy. Neurosci Lett 2010;478:29-31.
32. Igelstrom KM. Preclinical antiepileptic actions of selective serotonin reuptake inhibitors: implications for clinical trial design. Epilepsia 2012;53:596-605.
33. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) Summary basis of approval reports. Biol Psychiatr 2007;62:345-354.
34. Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 2011;7:462-472.
35. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-1539.
36. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis 2012;52:49-65.
37. Cramer JA, Blum D, Reed M, Fanning K; Epilepsy Impact Project Group. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003;4:515-521.
38. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007;75:192-196.
39. Kanner AM, Byrne RW, Chicharro AV, Wuu J, Frey M. Is a lifetime psychiatric history predictive of a worse postsurgical seizure outcome following a temporal lobectomy? Neurology 2009;72:793-799.
40. Richerson GB, Buchanan GF. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011;52(suppl 1):28-38.